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transplantation (SCT) for lymphomas and the engraftment of 
donor immnnocompetent cells is essential. The height of host 
"immunological barrier" belongs to the major factors influencing 
engraftment. Some patients transplanted after non myeloablative 
regimens finally reconstituted their own immunocompetent cells 
because of insufficient immunosuppression and there has been no 
room for GvL effect. On the other hand, many pretrcated 
immunocompromised r cipients developed severe complications 
due to unnecessary toxicity. 11 patients with non-hodgkin lym 
pbomas (NHL - 8x) and chronic lymphatic leukemia (CLL - 3x) 
underwent non-myeloablative allogeneie SCT fronl sibling donor. 
No one of them was in complete remision (CR) before SCT. The 
recipients with the pretransplant level of CD3+ cells below than 0, 
5x10 9/L were grafted after conditioning combined flndarabin 
(125rag/m2) and cyclophosphamide (120mg/kg). Those ones with 
CD3+ cells above 0, 5x10 9/L underwent SCT after fludarabin 
and melphalan (140rag/m2), fludarabin, melphalan and ATG 
(40mg/kg)or fludarabin, cyclophosphamide and ATG. The "graft 
versus host disease" (GvHD) prophyla~s consisted of cyclosporine 
A (CsA) only or CsA combined with the short-course of 
methotrexate (MTX). Donor chilnerism was evaluated in T-cell 
population at day +30, +60, +100 after SCT. CsA tapering 
depended on the grade of donor chimerism in T-cells. 10 patients 
(90, 0%) achieved complete donor chimerism in T-cells and sus- 
tained CR of their disease at the posttransplant follow-up period 
(median 134 days). 6 recipient (54, 5%) developed GvHD. 3 
patients (27, 3%) died of transplant-related complications. The 
combination of fludarabin and cyclophosphamide (+/- ATG) was 
associated with significantly lower to ,  city and allowed sufficient 
engraftment of donor cells with effective immunological mmour 
control in severe immunocompromised hosts. The reduction of 
conditioningorelated o,city without he decrease of CR rate fully 
advocate the pretransplant evaluation of T-cell populations in 
recipients. 
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COMPARISON OF THREE CONDITIONING REGIMENS FOR AUTOLOGOUS 
STEM CELL TRANSPLANTATION IN NON-HODGKINS LYMPHOMA 
Fein, S.G.; O[,ersteim E., GoochnaJ1, M.; Byrnes, J.; Fe1"mmde~, H.F. 
Hemc/tolo~JO71cologv, Uniz,e'rsio~ of3/lkmli, ~ limni, FL. 
The optimal conditioning regimen for non-Hodgkins Lynx- 
phoma (NHL) patients receiving autologous helnatopoietic stem 
cell (HSC) transplantation remains uncertain. In many centers, 
cyclophosphamide and total body irradiation (FBI) have been 
replaced by combination chemotherapy regimens. One of these is 
busulfan(BU) and oyclophosphamide(CY). Recent studies suggest 
that intravenous busulfan may be more efficacious than oral busul- 
fan, partly attributable to more predictable pharmacokineties. To 
compare these conditioning regimens, we reviewed 63 autologous 
HSC transplants performed at our institution fi'om 1994-2002. 
Among these, 22 patients with NHL (73 % interinediate or high 
grade) were treated with cyclophosphamide 120 mg/kg and TBI 
1200 cGy given as divided daily fractions for 3 days (Cy/TBI), 18 
patients (78% intermediate grade) with oral busulfan 16 mg/kg 
and eyclophosphamide 120 mg/kg (Oral Bu/Cy), and 23 patients 
(91% intermediate grade) with intravenous busulfan I2.8 mg/kg 
with cyelophosphamide 120 mg/kg (IV Bu/Cy). The median age 
for each of the three groups was comparable. The groups differed 
with respect o number of pre-transplant chemotherapy treat- 
ments- 36% of Cy/TBI heavily pre-treated (more than 8 cycles of 
chemotherapy), compared to 64% of oral Bu/Cy and 77% of IV 
Bu/Cy. The IV Bu/Cy patients were more likely to be pre-treated 
with rituximab (45%) than Cy/TBI (0%) and oral Bu/Cy (6%). 
Treatment-related toxicity and mortality were comparable, 
though both busulfan cohorts had a longer time to engraftment. 
Median follow-up times were 7.1 years (Cy/TBI), 3.6 years (oral 
Bu/Cy), and 2.1 years (IV Bu/Cy). Overall (OS) and relapse-free 
survivals (RFS) at two years were 77% and 59% (Cy/TBI), 61% 
and 56% (oral Bu/Cy), and 71% and 71% (IV Bu/Cy). Although 
follow-up is short, Kaplan-Meier survival analysis suggests a trend 
towards improved RFS among IV Bu/Cy patients. Log-rank com- 
parison of the OS curves reveals no significant,difference amongst 
the three groups. Based on this review, the to,city and efficacy 
are comparable using IV Bu/Cy, Cy/TBI or oral Bu/Cy, as the 
conditioning regimen in autologous HSC transplant for NHL. 
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AUTOLOGOUS HENATOPOIETIC STEM CELL TRANSPLANTATION FOR 
TREATMENT OF MULTICENTRIC CASTLEMAN'S DISEASE/POEMS 
SYNDROME 
ChaTnm'thy, U.; ffmmkirnma'a, N.; tGnnboj, G.; AbdeLRnheem, M.; 
Rl~y, ti2; Pnrikh, D. Hem / 07zc / BMT, Hem 7 FoJ'd He~dth @stem, 
Detroit, 1~iI. 
BACKGROUND: POEMS (polyneuropathy, organomegaly, 
endocrinopathy, M proteiu, skin changes) syndrome, a rare nmlti- 
systemic disorder, is associated with nmlticentric Castleman's dis- 
ease (MCD) in 50% of cases. The treatment of MCD remains a 
challenge. There have been reports of limited and variable effective- 
ness using steroids, chemotherapy and imlnnnomodnlators (anti- 
IL6, interferon, Rituximab). There has only been one previous case 
report (Repetto et al. 1986) using" HDCT/HSCT. We report a case 
of MCD/POEMS successfully treated with high dose chemothera- 
py (HDCT) and hematopoietic stem cell transplantation (HSCT). 
CASE RESENTATION: A previously healthy 24 year-old male 
presented witb a rapidly progressing (demyelinating/axonal) eu- 
ropathy, initially involving the lower, and eventually the upper 
extremities - around November 2000. Within three months the 
patient became wheel-chair bound (ECOG Performance status=4), 
developed generalized lymphadenopathy, hepato splenomegaly and 
gynecomastia. Lymph node and bone marrow biopsies were non- 
diagnostic. He undei~vent splenectomy in May, 2001. The patholo- 
gy showed angiofollicnlar hyperplasia consistent with Castleman's 
disease. He had low testosterone levels, Ig A ~ monoclonal protein 
in the serum, and cutaneous helnangiomas. Serologic screening for 
HIV and IIHV-8 were negative. With these findings, a diagnosis of 
MCD/POEMS was established. Therapeutic trials of steroids, Rit- 
nximab, IVIG, Cyelophosphamide/prednisone failed. Given his 
young age and rapid clinical deterioration he was offered high dose 
chemotherapy with HSCT. Peripheral blood stem cells were har- 
vested using Cyclophosphamide (3g/mZ)/G-CSF (10~tg/Kg). The 
patient was given Melphalan (200mg/m -~) as conditioning regimen, 
followed by antologons tem cell infusion. Hospital course was 
complicated by febrile neutropenia and choleeystitis. Clinical and 
radiological resolution of all lymphadenopathy occurred within 4 
weeks. He also had gradual recovery of his neurological deficits and 
hepatomegaly. The patient remains in remission a year later 
(ECOG PS=0) CONCLUSION High-dose chemotherapy with 
autologous hematopoietic stem cell transplant resulted in complete 
remission of aggressive and refractory MCD/POEMS syndrome 
with a durable response at one year. HDCT/HSCT is a novel treat 
ment option for this rare but challenging disease. 
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CD34+ COUNTS AFTER ETOPOSIDE AND CYCLOPHOSPHAMIDE PLUS 
G-CSF MOBILIZATION VERSUS G-CSF ALONE IN MULTIPLE MYELOMA 
PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION 
Pie'rce, T.N[; Scott, L.M.; White, M.; Agv~'_n, E.; Bero,mlm, R.B.; Ftlv, 
J. t,f,~; ~mzce, E.; Ph~eiro, L. . 
There were 83 patients who had an autologous transplant for 
multiple myeloma. All patients had a myeloablative r gimen with 
26 (31%) receiving" Melphalan, 55 (66%) received 
Melphalan/Total Body Irradiation (TBI). There was 1 patient 
who received ThioTepa/TBI and 1 who received Cyclophos- 
phamide/TBI as the conditioning regimen. Of the 83 pts, there 
were 58 (70%) who received mobilization with a continuous infu- 
sion of etoposide (2400mg/m2 over 34 hours) followed by 
cyclophosphamide 150 mg/kg followed by G-CSF at a dose of 5 
mcg/kg/day. There were 25 patients (30%) that received mobi 
lization with G-CSF only at a dose of 16 mcg/kg/day. For the 
patients who received chemotherapy mobilization, the average 
nmnber of PBSC collections required was 1.8 (Range 1 to 7, 
median=l). Of the patients who received G-CSF mobilization, the 
average number of collections was 2.8 (Range 1 to 5, median=2). 
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